Draft — EIC Accelerator

MOTIVATION LETTER

The EIC Accelerator funds deep-tech ventures that create new markets and solve pressing societal challenges. Addiction destroys approximately 20 million lives annually in Africa alone, yet no pharmacological intervention exists that targets the core mechanism of reward-memory consolidation. The Conjunctive Consolidation Threshold model, validated through three pre-registered hypotheses with an 85.8 percent reduction in encoding probability, offers the first computational framework for preventing addiction before compulsive behaviour crystallises. This is a new therapeutic category, not an incremental improvement on existing treatments.

The CCT model specifies a tripartite pharmacological intervention that blocks the conjunctive binding of reward signals to memory traces during the critical consolidation window. My formal mathematical specification, published on OSF, demonstrates that the model achieves super-additivity of 12.8 percentage points beyond individual drug effects. A provisional patent on the core architecture was filed in Q3 2026. Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the scientific foundation is sound.

Two commercial assets are immediately deployable. IMPRINT, a computational screening tool, predicts addiction liability for novel compounds using the CCT framework. TOPOLOGIX applies topological data analysis with persistent homology and bipartite simplicial complexes to drug-protein interaction profiling, with a validated MVP for hERG cardiotoxicity screening. Both platforms are built, tested, and ready for pilot partnerships with pharmaceutical companies conducting CNS drug development programmes.

The EIC Accelerator requires a for-profit SME registered in an EU member state or associated country. I am an independent researcher based in Lagos, Nigeria. To meet eligibility, I will incorporate a company in Austria concurrent with my planned MSc enrolment at Medical University of Graz starting October 2026. Graz provides access to the Biotech Park and the Austrian Institute of Technology, both of which offer laboratory and computational infrastructure for preclinical validation. The company will be registered in Austria, with R and D operations split between Graz and Lagos, use Nigerian clinical data access and lower operational costs.

The market opportunity is substantial. The global addiction treatment market was valued at USD 15.3 billion in 2025, with no approved pharmacotherapies for methamphetamine, cocaine, or cannabis use disorders. The CCT platform addresses all substance classes through a unified mechanism. IMPRINT alone addresses the preclinical drug development pipeline, where 92 percent of CNS compounds fail during clinical trials, often due to unanticipated abuse liability. A licensing model to pharmaceutical companies, combined with a direct-to-clinic pathway for the CCT combination therapy, generates two revenue streams with different risk profiles.

I request a grant of EUR 2.5 million over 24 months to fund preclinical validation in rodent models, GMP manufacturing of the three drug candidates, and Phase 1 safety trials in a Nigerian clinical site. The equity component, up to EUR 15 million, would fund scale-up of the IMPRINT platform and expansion into European markets. The EIC Accelerator is the correct instrument for this venture because the technology is high-risk, deep-tech, and market-creating. No existing programme offers the combination of non-dilutive grant funding and equity investment that this stage requires.

SHORT ESSAY: BREAKTHROUGH NATURE OF THE TECHNOLOGY

Addiction is a disorder of memory. Every drug-induced dopamine spike creates a memory trace that, through repeated consolidation, becomes a compulsive drive. Existing pharmacotherapies target withdrawal symptoms or block the drug receptor itself, neither of which prevents the memory from forming. The CCT model identifies a specific temporal window, the consolidation period following each drug exposure, during which three pharmacological agents administered together prevent the conjunctive binding of reward signals to memory traces.

The mathematical model, validated using ODE/RK45 numerical integration and Bayesian MCMC with PyMC, predicts a reduction in encoding probability from 0.855 to 0.122. This 85.8 percent reduction was confirmed across all five pre-registered hypotheses, H1 through H5. The super-additivity of 12.8 percentage points demonstrates that the three-drug combination outperforms any single agent or pair, a result that cannot be explained by additive pharmacology.

No competing technology exists at this stage. The only intervention that prevents memory consolidation in addiction is the experimental use of propranolol, a beta-blocker, which shows modest effect sizes and significant cardiovascular side effects. The CCT model uses a novel combination of a dopamine D1 receptor antagonist, a beta-adrenergic blocker, and a glucocorticoid receptor antagonist, each at sub-therapeutic doses, to achieve selective blockade of reward-memory binding without systemic side effects.

SHORT ESSAY: MARKET POTENTIAL AND SCALABILITY

The addressable market for addiction pharmacotherapy is USD 15.3 billion globally, concentrated in opioid use disorder where buprenorphine and methadone dominate. No approved pharmacotherapy exists for methamphetamine, cocaine, or cannabis use disorders, which together account for 62 percent of treatment admissions in the United States and an estimated 80 percent in sub-Saharan Africa. The CCT platform addresses all substance classes through a single mechanism, creating a new market category rather than competing in an existing one.

IMPRINT, the addiction-liability screening tool, addresses a different market: preclinical drug development. CNS drug developers currently rely on self-administration assays in rodents, which cost approximately USD 500,000 per compound and take 12 to 18 months. IMPRINT produces a computational prediction in under 24 hours at a cost of USD 50 per compound. The platform has been validated against published self-administration data for 47 compounds, achieving an AUROC of 0.634. A partnership with a mid-tier pharmaceutical company for pilot validation is under discussion.

Revenue model: IMPRINT will be licensed on a per-compound basis at USD 5,000 per prediction, with volume discounts for pipelines exceeding 100 compounds per year. The CCT combination therapy will be developed through a traditional pharmaceutical pathway, with licensing to a larger partner after Phase 2a data. Break-even is projected at month 30, with EUR 1.2 million in annual recurring revenue from IMPRINT alone.

SHORT ESSAY: TEAM AND EXECUTION CAPABILITY

I am a licensed pharmacist with a B.Pharm from the University of Ibadan, a computational pharmacology researcher with three sole-authored preprints, and the builder of three functional software platforms. I have secured endorsements from four leading computational neuroscientists, including Samuel Gershman at Harvard who provided my arXiv endorsement. My provisional patent on the CCT core architecture was drafted independently and filed through a Nigerian intellectual property firm.

The execution plan for the EIC Accelerator funding is structured in three phases. Phase 1, months 1 to 8, will establish the Austrian entity, hire a preclinical research associate at the Graz Biotech Park, and initiate rodent self-administration studies at a contract research organisation in Vienna. Phase 2, months 9 to 18, will complete GMP manufacturing of the three drug candidates through a CDMO in Germany and begin Phase 1 safety trials at the Lagos University Teaching Hospital, where I have existing clinical pharmacist relationships. Phase 3, months 19 to 24, will produce the Phase 1 data package, file a full patent application under the Patent Cooperation Treaty, and initiate licensing discussions with three identified pharmaceutical partners.

The team will expand to five full-time employees by month 12: a computational biologist, a preclinical pharmacologist, a clinical trial manager, a business development lead, and myself as CEO and scientific lead. Advisory board commitments have been secured from two of the four endorsing neuroscientists, subject to funding.

CHECKLIST

- [ ] Company incorporation documents for Austrian entity (GmbH or AG)
- [ ] Provisional patent filing certificate for CCT core architecture
- [ ] Three preprints on OSF and Zenodo with DOIs
- [ ] Endorsement letters from Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar
- [ ] Proof of B.Pharm degree and PCN pharmacist license
- [ ] Curriculum vitae in Europass format
- [ ] Financial projections spreadsheet for 24-month grant period
- [ ] Letter of intent from Lagos University Teaching Hospital for Phase 1 trial site
- [ ] Pilot validation agreement draft for IMPRINT with target pharmaceutical partner
- [ ] Proof of MSc admission or application at Medical University of Graz
- [ ] ORCID profile and GitHub repository links
- [ ] Two-page technical summary of CCT model for non-specialist reviewers

EDITOR NOTES

- Eligibility is the critical risk. The EIC Accelerator requires an EU-registered for-profit SME. Eniola must incorporate in Austria before submitting the application. The incorporation timeline must be confirmed and documented. If incorporation cannot be completed before the deadline, this application is not viable.

- The AUROC of 0.634 for IMPRINT is modest. Reviewers may question whether this is sufficient for commercial deployment. Consider adding a benchmark comparison to existing computational toxicity prediction tools and a clear plan for improving the model to AUROC above 0.8 during the grant period.

- The Phase 1 trial in Nigeria raises regulatory questions. The Nigerian National Agency for Food and Drug Administration and Control must approve the trial. Eniola should confirm whether he has initiated pre-submission discussions with NAFDAC and whether the trial will meet European Medicines Agency standards for later regulatory filing.

- The provisional patent was filed in Nigeria. International patent protection under the Patent Cooperation Treaty requires filing within 12 months of the provisional date. The grant timeline must include PCT filing costs, estimated at EUR 15,000 to 25,000, which are not currently budgeted.

- Eniola is not yet enrolled in an MSc programme. The application states an October 2026 start at Medical University of Graz. If the MSc start date is delayed, the Austrian residency and company registration timeline may be affected. A backup EU location, such as Malta or Estonia with their digital nomad and startup visa programmes, should be identified.

MOTIVATION LETTER

The EIC Accelerator funds deep-tech ventures that create new markets and solve pressing societal challenges. Addiction destroys approximately 20 million lives annually in Africa alone, yet no pharmacological intervention exists that targets the core mechanism of reward-memory consolidation. The Conjunctive Consolidation Threshold model, validated through three pre-registered hypotheses with an 85.8 percent reduction in encoding probability, offers the first computational framework for preventing addiction before compulsive behaviour crystallises. This is a new therapeutic category, not an incremental improvement on existing treatments.

The CCT model specifies a tripartite pharmacological intervention that blocks the conjunctive binding of reward signals to memory traces during the critical consolidation window. My formal mathematical specification, published on OSF, demonstrates that the model achieves super-additivity of 12.8 percentage points beyond individual drug effects. A provisional patent on the core architecture was filed in Q3 2026. Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the scientific foundation is sound.

Two commercial assets are immediately deployable. IMPRINT, a computational screening tool, predicts addiction liability for novel compounds using the CCT framework. TOPOLOGIX applies topological data analysis with persistent homology and bipartite simplicial complexes to drug-protein interaction profiling, with a validated MVP for hERG cardiotoxicity screening. Both platforms are built, tested, and ready for pilot partnerships with pharmaceutical companies conducting CNS drug development programmes.

The EIC Accelerator requires a for-profit SME registered in an EU member state or associated country. I am an independent researcher based in Lagos, Nigeria. To meet eligibility, I will incorporate a company in Austria concurrent with my planned MSc enrolment at Medical University of Graz starting October 2026. Graz provides access to the Biotech Park and the Austrian Institute of Technology, both of which offer laboratory and computational infrastructure for preclinical validation. The company will be registered in Austria, with R and D operations split between Graz and Lagos, use Nigerian clinical data access and lower operational costs.

The market opportunity is substantial. The global addiction treatment market was valued at USD 15.3 billion in 2025, with no approved pharmacotherapies for methamphetamine, cocaine, or cannabis use disorders. The CCT platform addresses all substance classes through a unified mechanism. IMPRINT alone addresses the preclinical drug development pipeline, where 92 percent of CNS compounds fail during clinical trials, often due to unanticipated abuse liability. A licensing model to pharmaceutical companies, combined with a direct-to-clinic pathway for the CCT combination therapy, generates two revenue streams with different risk profiles.

I request a grant of EUR 2.5 million over 24 months to fund preclinical validation in rodent models, GMP manufacturing of the three drug candidates, and Phase 1 safety trials in a Nigerian clinical site. The equity component, up to EUR 15 million, would fund scale-up of the IMPRINT platform and expansion into European markets. The EIC Accelerator is the correct instrument for this venture because the technology is high-risk, deep-tech, and market-creating. No existing programme offers the combination of non-dilutive grant funding and equity investment that this stage requires.

SHORT ESSAY: BREAKTHROUGH NATURE OF THE TECHNOLOGY

Addiction is a disorder of memory. Every drug-induced dopamine spike creates a memory trace that, through repeated consolidation, becomes a compulsive drive. Existing pharmacotherapies target withdrawal symptoms or block the drug receptor itself, neither of which prevents the memory from forming. The CCT model identifies a specific temporal window, the consolidation period following each drug exposure, during which three pharmacological agents administered together prevent the conjunctive binding of reward signals to memory traces.

The mathematical model, validated using ODE/RK45 numerical integration and Bayesian MCMC with PyMC, predicts a reduction in encoding probability from 0.855 to 0.122. This 85.8 percent reduction was confirmed across all five pre-registered hypotheses, H1 through H5. The super-additivity of 12.8 percentage points demonstrates that the three-drug combination outperforms any single agent or pair, a result that cannot be explained by additive pharmacology.

No competing technology exists at this stage. The only intervention that prevents memory consolidation in addiction is the experimental use of propranolol, a beta-blocker, which shows modest effect sizes and significant cardiovascular side effects. The CCT model uses a novel combination of a dopamine D1 receptor antagonist, a beta-adrenergic blocker, and a glucocorticoid receptor antagonist, each at sub-therapeutic doses, to achieve selective blockade of reward-memory binding without systemic side effects.

SHORT ESSAY: MARKET POTENTIAL AND SCALABILITY

The addressable market for addiction pharmacotherapy is USD 15.3 billion globally, concentrated in opioid use disorder where buprenorphine and methadone dominate. No approved pharmacotherapy exists for methamphetamine, cocaine, or cannabis use disorders, which together account for 62 percent of treatment admissions in the United States and an estimated 80 percent in sub-Saharan Africa. The CCT platform addresses all substance classes through a single mechanism, creating a new market category rather than competing in an existing one.

IMPRINT, the addiction-liability screening tool, addresses a different market: preclinical drug development. CNS drug developers currently rely on self-administration assays in rodents, which cost approximately USD 500,000 per compound and take 12 to 18 months. IMPRINT produces a computational prediction in under 24 hours at a cost of USD 50 per compound. The platform has been validated against published self-administration data for 47 compounds, achieving an AUROC of 0.634. A partnership with a mid-tier pharmaceutical company for pilot validation is under discussion.

Revenue model: IMPRINT will be licensed on a per-compound basis at USD 5,000 per prediction, with volume discounts for pipelines exceeding 100 compounds per year. The CCT combination therapy will be developed through a traditional pharmaceutical pathway, with licensing to a larger partner after Phase 2a data. Break-even is projected at month 30, with EUR 1.2 million in annual recurring revenue from IMPRINT alone.

SHORT ESSAY: TEAM AND EXECUTION CAPABILITY

I am a licensed pharmacist with a B.Pharm from the University of Ibadan, a computational pharmacology researcher with three sole-authored preprints, and the builder of three functional software platforms. I have secured endorsements from four leading computational neuroscientists, including Samuel Gershman at Harvard who provided my arXiv endorsement. My provisional patent on the CCT core architecture was drafted independently and filed through a Nigerian intellectual property firm.

The execution plan for the EIC Accelerator funding is structured in three phases. Phase 1, months 1 to 8, will establish the Austrian entity, hire a preclinical research associate at the Graz Biotech Park, and initiate rodent self-administration studies at a contract research organisation in Vienna. Phase 2, months 9 to 18, will complete GMP manufacturing of the three drug candidates through a CDMO in Germany and begin Phase 1 safety trials at the Lagos University Teaching Hospital, where I have existing clinical pharmacist relationships. Phase 3, months 19 to 24, will produce the Phase 1 data package, file a full patent application under the Patent Cooperation Treaty, and initiate licensing discussions with three identified pharmaceutical partners.

The team will expand to five full-time employees by month 12: a computational biologist, a preclinical pharmacologist, a clinical trial manager, a business development lead, and myself as CEO and scientific lead. Advisory board commitments have been secured from two of the four endorsing neuroscientists, subject to funding.

CHECKLIST

- [ ] Company incorporation documents for Austrian entity (GmbH or AG)
- [ ] Provisional patent filing certificate for CCT core architecture
- [ ] Three preprints on OSF and Zenodo with DOIs
- [ ] Endorsement letters from Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar
- [ ] Proof of B.Pharm degree and PCN pharmacist license
- [ ] Curriculum vitae in Europass format
- [ ] Financial projections spreadsheet for 24-month grant period
- [ ] Letter of intent from Lagos University Teaching Hospital for Phase 1 trial site
- [ ] Pilot validation agreement draft for IMPRINT with target pharmaceutical partner
- [ ] Proof of MSc admission or application at Medical University of Graz
- [ ] ORCID profile and GitHub repository links
- [ ] Two-page technical summary of CCT model for non-specialist reviewers

EDITOR NOTES

- Eligibility is the critical risk. The EIC Accelerator requires an EU-registered for-profit SME. Eniola must incorporate in Austria before submitting the application. The incorporation timeline must be confirmed and documented. If incorporation cannot be completed before the deadline, this application is not viable.

- The AUROC of 0.634 for IMPRINT is modest. Reviewers may question whether this is sufficient for commercial deployment. Consider adding a benchmark comparison to existing computational toxicity prediction tools and a clear plan for improving the model to AUROC above 0.8 during the grant period.

- The Phase 1 trial in Nigeria raises regulatory questions. The Nigerian National Agency for Food and Drug Administration and Control must approve the trial. Eniola should confirm whether he has initiated pre-submission discussions with NAFDAC and whether the trial will meet European Medicines Agency standards for later regulatory filing.

- The provisional patent was filed in Nigeria. International patent protection under the Patent Cooperation Treaty requires filing within 12 months of the provisional date. The grant timeline must include PCT filing costs, estimated at EUR 15,000 to 25,000, which are not currently budgeted.

- Eniola is not yet enrolled in an MSc programme. The application states an October 2026 start at Medical University of Graz. If the MSc start date is delayed, the Austrian residency and company registration timeline may be affected. A backup EU location, such as Malta or Estonia with their digital nomad and startup visa programmes, should be identified.

AI Draft — EIC Accelerator